CLL | Tumor

Survival May Be Possible for Patients With CLL Even With Small Amounts of Disease After Treatment

October 14th 2021

Detectable amounts of minimal residual disease after treatment for CLL does not mean that all hope is lost for survival without disease progression.

WHO Adds Cancer and Smoking Cessation Medicines to Essential Drug List

October 6th 2021

The World Health Organization updated their Model Lists of Essential Medicines to include more cancer treatments, though some popular cancer drugs were excluded from the list.

3 Things Cancer Survivors Need to Remember: From Someone Who Has Been There

October 4th 2021

“Spending over a third of my life as a cancer survivor, I’ve learned a few lessons along the way,” said Lacey, who was diagnosed with chronic lymphocytic leukemia 13 years ago.

Which Mask Is Best for Protecting Patients With Cancer From a COVID-19 Variant?

September 27th 2021

An expert explains virus mutations, the Delta variant of COVID-19 and which masks offer the best protection for patients with cancer.

Blood Cancer Survivors Should Not Rely on COVID-19 Antibody Tests to Determine Immunity

August 24th 2021

Patients with blood cancers may be less likely to derive immunity from the COVID-19 vaccine, though antibody tests should not be the end-all-be-all in guiding their behavior.

BTK Inhibitors Are the Path Forward in Frontline CLL Treatment

August 19th 2021

Patients with chronic lymphocytic leukemia should talk to their doctors about the use of BTK inhibitors, as they produced promising outcomes in multiple trials.

CLL Treatment Represents ‘Very Optimistic Area’ in Research

August 9th 2021

Outcomes in patients with CLL continue to improve with the emergence of targeted drugs and immunotherapy.

Navigating Chronic Lymphocytic Leukemia Diagnosis and Staging

July 28th 2021

Although CLL follows a different staging format than other cancer types, diagnosing the disease properly can open the doors for more effective treatment and management strategies.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26th 2021

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Study Analyzes Quality of Life Research on Patients With CLL and Their Caregivers

July 22nd 2021

More research is needed on how a chronic lymphocytic leukemia diagnosis can affect patients and their caregivers.

Novel BTK Inhibitor Well Tolerated in Patients with CLL, Other B-Cell Malignancies

July 21st 2021

TG-1701 monotherapy or added to ublituximab and Ukoniq contributed to early complete responses in patients with B-cell malignancies.

Drug Duo Boosts Outcomes in Elderly Patients With CLL

July 18th 2021

Fixed-duration Venclexta plus Gazyva produced longer remissions than chemoimmunotherapy in elderly patients with chronic lymphocytic leukemia and other comorbidities.

Imbruvica-Venclexta Combo Superior to Chlorambucil-Obinutuzumab for CLL

June 16th 2021

The combination of Imbruvica with Venclexta significantly reduced the risk for progression or death by 78% compared with chlorambucil plus obinutuzumab.

Front-Line Imbruvica-Venclexta Combo May Induce Durable Responses in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

June 10th 2021

Treatment with this combination was associated with encouraging clinical responses in this patient population.

Calquence and Imbruvica Elicit Similar Survival Results in Previously Treated Patients with Type of Leukemia

June 8th 2021

Although survival rates were similar, patients with chronic lymphocytic leukemia treated with Calquence experienced fewer side effects than those who received Imbruvica.

Cirmtuzumab Plus Imbruvica Led to Increased Response Rates in MCL and CLL

June 7th 2021

Cirmtuzumab plus Imbruvica led to an 83.3% overall response rate, with 38.9% complete response and 44.4% partial response rate, in patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Imbruvica Plus Ublituximab Safely Improves Response Rate for High-Risk Chronic Lymphocytic Leukemia

April 23rd 2021

Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.

Gazyva With Chemotherapy Shows Promise for Chronic Lymphocytic Leukemia

April 22nd 2021

Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.

Imbruvica Plus Novel Agent May Improve Progression-Free Survival in Chronic Lymphocytic Leukemia

March 3rd 2021

Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.

Marialice’s Story with Chronic Lymphocytic Leukemia (CLL)

February 19th 2021

Treating CLL with CALQUENCE® (acalabrutinib)

First Patient to Receive CAR-T Cell Therapy Dies, Cancer Organizations Appeal to President Biden for COVID-19 Vaccine Priority Access, and More

February 19th 2021

From the death of Bill Ludwig, the first patient to receive CAR-T cell therapy to treat his end-stage CLL, to a letter to the President urging him to grant patients with cancer and survivors priority access to the COVID-19 vaccine, here’s what’s happening in the cancer space this week.

Adding to the Regimen: NCCN Updates in Leukemia and Lymphoma

February 15th 2021

The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.

Addressing Unmet Needs in CLL

February 2nd 2021

CLL: An Early Clinical Trial With Ibrutinib

February 2nd 2021

CAR T-Cells: Refining CLL Therapy With Clinical Trials

February 2nd 2021

CLL Versus Other Leukemia Types

February 2nd 2021

CLL Society: Smart Patients Get Smart Care

February 1st 2021

Treatment Options in Relapsed CLL

February 1st 2021

Initiating Therapy in CLL

February 1st 2021

Options for Managing Refractory CLL

February 1st 2021